Comparing intravitreal triamcinolone acetonide and bevacizumab injections for the treatment of diabetic macular oedema: a randomized double- blind study

Página do item simplificado
dc.creatorIsaac, David Leonardo Cruvinel
dc.creatorAbud, Murilo Batista
dc.creatorFrantz, Kariza Aiko
dc.creatorRassi, Alan Ricardo
dc.creatorÁvila, Marcos Pereira de
dc.date.accessioned2019-05-16T14:26:13Z
dc.date.available2019-05-16T14:26:13Z
dc.date.issued2012
dc.description.abstractPurpose: To compare the effect of a single intravitreal injection of triamcinolone acetonide and bevacizumab in reducing macular thickness, which was measured by optical coherence tomography (OCT) in patients with diabetic macular oedema (DMO). Methods: The patients received a single intravitreal injection of 1.25 mg bev- acizumab in one randomly selected eye and 4.0 mg triamcinolone acetonide in the contralateral eye. Central foveal thickness measurement (CFT) with OCT was taken at the initial visit and at the 4-week, 12-week and 24-week visits. Results: Eleven patients (22 eyes) were enrolled and statistically analysed. CFT reduced in the eyes treated with triamcinolone and those treated with bevacizumab in weeks 4 and 12 (p < 0.05). At the 24-week follow-up, no significant difference was noted, relative to the initial visit. Comparing the two groups treated with dif- ferent drugs, a statistically significant difference in CFT in weeks 4 and 12 was noted, with a more significant reduction in triamcinolone-treated eyes (p < 0.05). Regarding visual acuity (VA), patients treated with triamcinolone had improvement in VA at 4-week (p = 0.02) and 12-week follow-up (p = 0.01), while the group treated with bevacizumab had VA improvement at 4 -week follow-up (p = 0.02). Among the eyes treated with triamcinolone, intraocular pressure (IOP) measure- ment of more than 21 mmHg was found in three eyes (27.3%). Conclusions: Intravitreal triamcinolone proved to be more efficient in reducing DMO, providing longer lasting visual improvement, relative to bevacizumab. Eyes treated with triamcinolone had the highest percentage increase in IOP. Further studies are needed to corroborate these findings.pt_BR
dc.identifier.citationISAAC, David Leonardo Cruvinel et al. Comparing intravitreal triamcinolone acetonide and bevacizumab injections for the treatment of diabetic macular oedema: a randomized double-blind study. Acta Ophthalmologica, Hoboken, v. 90, p. 56-60, 2012.pt_BR
dc.identifier.doi10.1111/j.1755-3768.2009.01817.X
dc.identifier.urihttp://repositorio.bc.ufg.br/handle/ri/17533
dc.language.isoengpt_BR
dc.publisher.countryEstados unidospt_BR
dc.publisher.departmentFaculdade de Medicina - FM (RG)pt_BR
dc.rightsAcesso Abertopt_BR
dc.subjectBevacizumabpt_BR
dc.subjectComplications from diabetespt_BR
dc.subjectDiabetic retinopathypt_BR
dc.subjectVisual acuitypt_BR
dc.subjectMacular oedema ⁄ therapypt_BR
dc.subjectTriamcinolone acetonide ⁄ therapeutic usept_BR
dc.subjectTriamcinolone acetonide ⁄ administration & dosagept_BR
dc.titleComparing intravitreal triamcinolone acetonide and bevacizumab injections for the treatment of diabetic macular oedema: a randomized double- blind studypt_BR
dc.typeArtigopt_BR

Arquivos

Pacote Original
Agora exibindo 1 - 1 de 1
Imagem de Miniatura
Nome:
Artigo - David Leonardo Cruvinel Isaac - 2012.pdf
Tamanho:
312.87 KB
Formato:
Adobe Portable Document Format
Baixar
Licença do Pacote
Agora exibindo 1 - 1 de 1
Nenhuma Miniatura disponível
Nome:
license.txt
Tamanho:
1.71 KB
Formato:
Item-specific license agreed upon to submission
Descrição:
Baixar

Coleções

FM - Artigos publicados em periódicos